

Humber Area Prescribing Committee

Date / Time	1 st November 2023 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	Yes

Attendance	<p>Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR)</p> <p>Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)</p> <p>Luke Storr – Senior Pharmacy Technician, HUTH (LS)</p> <p>Prof A Morice, Professor of Respiratory Medicine HUTH, Chair of HUTH D&TC- (AM)</p> <p>Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS)</p> <p>Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB)</p> <p>Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)</p> <p>Narayana Pothina- Consultant in adult medicine, NLAG (NP) (From 2pm)</p> <p>Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)</p> <p>Daniel Newsome- Principal Pharmacist RDTC (DN)</p> <p>Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH)</p> <p>Simon Priestley- Chief Pharmacist, NLAG (SP)</p> <p>Joanne Goode – Chief Pharmacist – HUTH (JG)</p> <p>Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC)</p> <p>Dr Pratik Basu- GP- The Birches medical practice (PB) (From 2pm)</p> <p>Dr Rolan Schreiber, Professional Secretary LMC (RSc)</p>
-------------------	---

Apologies	<p>Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc)</p> <p>Emma Baggaley - Assistant Director Medicines Management CHCP</p>
------------------	---

Agenda Number	Item	Discussion	Action	Lead	Due Date
2023.11.01	Apologies	Noted above			
2023.11.02	Declarations of interest	None			
2023.11.03	Minutes of previous meeting	Accepted as true record			
2023.11.04	Action Tracker	<p>Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) June 2023: In progress July 2023: In progress August 2023: Received info from CHCP/HFT, JM to prepare new document September 2023: In progress October 2023: In progress November 2023: In progress</p> <p>Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF September update: JM to contact Rachel Ainger October update: October 2023: JM attended ICB wide meeting regarding preparing ICB SCF and progressing monitoring. JM/AK to continue to attend meeting to progress SCF November update: To complete action here – as progressing via SCF group.</p> <p>Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) JM to provide RS information on number of patients in NEL/NL</p>	<p>Ongoing</p> <p>Complete</p> <p>Ongoing</p>	<p>AK/JM</p> <p>JM</p> <p>JM</p>	<p>2/24</p> <p>12/23</p> <p>12/23</p>

		<p>December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole</p> <p>February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL).</p> <p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>April update: Riluzole to JM to update websites to include NL</p> <p>May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review</p> <p>June update: Modafinil still waiting on NL, JM to review mycophenolate for July guideline group</p> <p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group</p> <p>August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group</p> <p>September update: For September guideline group</p> <p>October 2023 update: For November Guideline group</p> <p>November 2023 update: For November Guideline group</p> <p>Outstanding actions from HERPC</p> <p>Renal repatriation:</p> <p>November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time.</p> <p>December update – Not met with renal yet.</p> <p>March update – Updating business case.</p> <p>May update – to meet with NHSE</p> <p>August update – not yet met with NHSE</p> <p>September update - not yet met with NHSE</p> <p>October update: not yet met with NHSE</p> <p>November update: not yet met with NHSE</p> <p>Ratification of joint formulary</p> <p>To add chapter 1 to netformulary (and remove HERPC chapter when complete)</p> <p>September 2023 update: currently available products; to add new products still and remove HERPC chapter</p> <p>October 2023 update: net Formulary update complete and links built in. Removing HERPC chapter 1 still outstanding</p> <p>November 2023 update: Action complete</p>	Ongoing	JM	12/23
		<p>Ratification of joint formulary</p> <p>To add chapter 1 to netformulary (and remove HERPC chapter when complete)</p> <p>September 2023 update: currently available products; to add new products still and remove HERPC chapter</p> <p>October 2023 update: net Formulary update complete and links built in. Removing HERPC chapter 1 still outstanding</p> <p>November 2023 update: Action complete</p>	Complete	JM/AK/LS	11/23

		<p>Blueteq Non-compliance to NICE guidance in acute trusts and financial impact June update: JM to submit ustekinumab report in gastroenterology HUTH when approved JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved July update: JM to update next time. August update: no further update, infliximab audit in HUTH started September update: HUTH audit still ongoing October update: HUTH audits still ongoing November update: HUTH audits still ongoing</p> <p>Ratification of guidelines and SCFs Infliximab in ASUC – to add additional information and re-present when updated July update: JM to update for next meeting, AK provided info requested August update: Awaiting information from pathology September update: To finalise document and send to chief pharmacists for comment October update: Sent to chief pharmacists for comment November update: To add to December agenda</p> <p>AOB – ondansetron Pathway to be referred to NLAG M&T and to appropriate meeting in Northern Lincolnshire places August update – M&T cancelled due to junior doctor strikes October update – Awaiting pathway to presented at M&T November update – action closed for APC. Action is for M&T to discuss pathway; APC classification is still red.</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway; to enable JM to start writing paper.</p>	Ongoing	JM	12/23
			Ongoing	JM	11/23
			Complete	AK	12/23
			Ongoing	JM	12/23

		<p>September update: September D&TC next week, further updates to pathway needed</p> <p>October update: Awaiting updated pathway</p> <p>November update: Awaiting updated pathway; further updates need and prioritised adalimumab switch.</p> <p>Ratification of guidelines and SCFs: Sick Day Guidance in T2DM</p> <p>JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team</p> <p>October 2023: ongoing</p> <p>November 2023: ongoing</p>	Ongoing	JM	11/23
		<p>Ratification of guidelines and SCFs: Amiodarone SCF</p> <p>JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH</p> <p>September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites</p> <p>October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG.</p> <p>November 2023 – to be discussed at next cardiology governance</p>	Ongoing	JM	11/23
		<p>Ratification of guidelines and SCFs</p> <p>JM/AK to update formulary to match all asthma 3 guideline</p> <p>October update: ongoing</p>	Ongoing	JM/AK	1/24
		<p>Traffic light status</p> <p>JM/AK to update netFormulary</p>	Action Complete	JM/AK	11/23
		<p>Traffic light status</p> <p>JM/LS to update HERPC formulary</p>	Action Complete	JM/LS	11/23
		<p>Traffic light status</p> <p>JM/LS to update HERPC red list</p>	Action Complete	JM/LS	11/23
		<p>Feedback from Integrated Medicines Optimisation Committee</p> <p>Sodium valproate prevent compliance</p> <p>November update: To circulate report that goes to IPMOC from primary care audits</p>	Ongoing	JM/KMc	12/23
		<p>Ratification of guidelines and SCFs – azithromycin</p> <p>AK to discuss guidance with Dr Yasso</p> <p>November update: Discussed with Dr Yasso who is happy with the internal NLAG document. To add links to</p>	Ongoing	AK/JM	12/23

		<p>Azithromycin monograph in netFormulary for NICE guidance and asthma guidance.</p> <p>Ratification of guidelines and SCFs – ranolazine To add to joint formulary agenda for review of classification</p> <p>Ratification of guidelines and SCFs – JIC medication leaflet AK to send to St Andrews Hospice GP team November update – contacted clinical directors and they were happy with content. Given a contact for logos and awaiting response</p> <p>Ratification of guidelines and SCFs JM to upload approved guidance, link into netFormulary and remove HERPC/NLAPC guidance</p> <p>Ratification of guidelines and SCFs – dienogest JM to add classification to joint formulary agenda</p> <p>Ratification of guidelines and SCFs – rifaximin JM to sort minor update</p> <p>Correspondence received JM to draft letter regarding dosulepin</p> <p>AOB JM to add statement on netFormulary around insulin needle cost</p>	<p>Action Complete</p> <p>Ongoing</p> <p>Action Complete</p> <p>Action Complete</p> <p>Action Complete</p> <p>Action Complete</p> <p>Action Complete</p>	<p>JM</p> <p>AK</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>11/23</p> <p>11/23</p> <p>11/23</p> <p>11/23</p> <p>11/23</p> <p>11/23</p> <p>11/23</p>
2023.11.05	Traffic Light Status	<p>Difelikefalin- proposed as RED</p> <p>Letermovir- proposed as RED in line with TA591</p> <p>Ibuprofen IV- proposed as RED</p> <p>Benzbromarone- proposed as RED (unlicensed medicine)</p>	Update formularies/red list	JM/LS/AK	12/23
2023.11.06	Feedback from Integrated Medicines Optimisation Committee	<p>NICE TAs for rimegepant (TA906) and dapagliflozin (TA902) escalated to ICB executive for sign off. Semaglutide (TA875) is also going to be escalated to ICB executive.</p> <p>ICB Clinical Policy Review Group to look at tier 3 weight management services across patch.</p> <p>ADHD medication shared care discussed in light of current supply issues and review of national shared care. Recommended that any new shared care are looked at system wide rather than looking at place.</p>	Noted		
2023.11.07	Work plans	<p>a) Joint formulary alignment</p> <p>b) Shared care frameworks</p> <p>c) Guidelines</p>	Ongoing for information only		
2023.11.08	Ratification of guidelines and SCFs	<p>a) Amber Guidance Migraine – updated with eptinezumab and rimegapant for episodic migraine. Will need updating again soon for next rimegapant TA.</p>	a) Approved (pending approval of TA906)	JM	12/23

		<ul style="list-style-type: none"> b) Blood glucose formulary – minor update however NHSE have updated the national document and more feedback sent around meters for elderly patients with dexterity issues without smart phones c) Infant nutrition – minor update with removal of discontinued product 	<ul style="list-style-type: none"> b) Approved- NHSE released further updates. Will update and re send to APC c) Approved- updated 		
2023.11.09	Ratification of joint formulary	<ul style="list-style-type: none"> • Chapter 6 – final document from joint formulary. One removal required that not been discussed at joint formulary (discontinuation of lixisenatide). To upload onto netFormulary 	Approved	JM/AK/LS	3/24
2023.11.10	RTDC updates	<ul style="list-style-type: none"> • Sept 23- to update formulary with TAs in timescale and MHRA DSU 	Update formulary/red list	JM/LS/AK	12/23
2023.11.11	Other issues	<ul style="list-style-type: none"> a) Safety Needles – Discussion of when insulin pen needles should be prescribed by GP and when should be supplied by employing organisation. Committee agreed that when employees administering medicines that it is a staff safety issue so is employing agencies responsibility. However, as currently being prescribed by GPs in Hull and ERY would need further work in these areas to move additional budget for purchasing by CHCP (from prescribing). b) Rocket IPC – respiratory and oncology place Rocket IPC devices and patients then seen by district nursing to use the drain. District nursing requesting prescriptions for the devices. Discussions around who should be prescribing the device for the district nursing team to use and committee felt the specialist team or team using the devices should be prescribing. 	<ul style="list-style-type: none"> a) add info onto formulary b) RSc to discuss with LMC Interface Officer and to feedback to HUTH via contracts meeting. 	JM RSc	12/23 12/23
2023.11.12	Minutes from subcommittees	<ul style="list-style-type: none"> a) Joint formulary subcommittee (Aug 2023) b) Guideline subcommittee (Nil this month) 	Attached for info only		
2023.11.13	Additional minutes for information	<ul style="list-style-type: none"> a) HUTH D&TC (Sept 2023) b) HFT DTG (Nil) c) NLAG M&T (Nil) d) NYY APC (Sept 2023) 	Attached for info only		
2023.11.14	Correspondence received	Nil this month			
2023.11.15	AOB	<ul style="list-style-type: none"> • SR raise a point concerning Spire over turnaround of medication. RSc to contact Spire • PB raised an issue about availability of oxygen for cluster headache on South Bank. To discuss with RS outside meeting 	To contact Spire via contract team No further action required	RSc	12/23
2023.11.16	Date of next meeting	6 th December 13.00 – 15.00 Teams			

